FENNEC PHARMACEUTICALS INC (FENC)
CA31447P1009 - Common Stock
FENC gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 581 industry peers in the Biotechnology industry. FENC has only an average score on both its financial health and profitability. FENC is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
FENC had positive earnings in the past year.
In the past year FENC had a positive cash flow from operations.
In the past 5 years FENC always reported negative net income.
In the past 5 years FENC always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 4.11%, FENC belongs to the best of the industry, outperforming 95.34% of the companies in the same industry.
FENC has a Return On Equity of 94.39%. This is amongst the best in the industry. FENC outperforms 99.83% of its industry peers.
FENC has a Return On Invested Capital of 8.30%. This is amongst the best in the industry. FENC outperforms 95.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 94.39% | ||
| ROIC | 8.3% |
ROA(3y)-75.05%
ROA(5y)-74.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 6.33%, FENC belongs to the top of the industry, outperforming 95.16% of the companies in the same industry.
FENC's Operating Margin of 13.87% is amongst the best of the industry. FENC outperforms 95.85% of its industry peers.
FENC has a better Gross Margin (96.16%) than 96.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.87% | ||
| PM (TTM) | 6.33% | ||
| GM | 96.16% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FENC has more shares outstanding than it did 1 year ago.
FENC has more shares outstanding than it did 5 years ago.
FENC has a worse debt/assets ratio than last year.
2.2 Solvency
FENC has an Altman-Z score of -0.53. This is a bad value and indicates that FENC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.53, FENC is in line with its industry, outperforming 57.34% of the companies in the same industry.
FENC has a debt to FCF ratio of 19.80. This is a negative value and a sign of low solvency as FENC would need 19.80 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 19.80, FENC belongs to the best of the industry, outperforming 93.96% of the companies in the same industry.
A Debt/Equity ratio of 9.95 is on the high side and indicates that FENC has dependencies on debt financing.
FENC has a Debt to Equity ratio of 9.95. This is amonst the worse of the industry: FENC underperforms 84.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 9.95 | ||
| Debt/FCF | 19.8 | ||
| Altman-Z | -0.53 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
FENC has a Current Ratio of 6.93. This indicates that FENC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.93, FENC is in the better half of the industry, outperforming 64.94% of the companies in the same industry.
A Quick Ratio of 6.72 indicates that FENC has no problem at all paying its short term obligations.
FENC has a Quick ratio of 6.72. This is in the better half of the industry: FENC outperforms 64.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.93 | ||
| Quick Ratio | 6.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 103.03% over the past year.
Looking at the last year, FENC shows a very strong growth in Revenue. The Revenue has grown by 1296.34%.
FENC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 400.02% yearly.
EPS 1Y (TTM)103.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%278.26%
Revenue 1Y (TTM)1296.34%
Revenue growth 3Y400.02%
Revenue growth 5YN/A
Sales Q2Q%1413.42%
3.2 Future
The Earnings Per Share is expected to grow by 61.33% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 57.29% on average over the next years. This is a very strong growth
EPS Next Y190.57%
EPS Next 2Y71.1%
EPS Next 3Y70.66%
EPS Next 5Y61.33%
Revenue Next Year214.39%
Revenue Next 2Y81.11%
Revenue Next 3Y67.34%
Revenue Next 5Y57.29%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 226.00, the valuation of FENC can be described as expensive.
93.26% of the companies in the same industry are more expensive than FENC, based on the Price/Earnings ratio.
FENC is valuated expensively when we compare the Price/Earnings ratio to 28.05, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 11.98, the valuation of FENC can be described as very reasonable.
FENC's Price/Forward Earnings ratio is rather cheap when compared to the industry. FENC is cheaper than 96.72% of the companies in the same industry.
FENC's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 20.07.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 226 | ||
| Fwd PE | 11.98 |
4.2 Price Multiples
FENC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. FENC is cheaper than 94.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 121.28 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
FENC's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as FENC's earnings are expected to grow with 70.66% in the coming years.
PEG (NY)1.19
PEG (5Y)N/A
EPS Next 2Y71.1%
EPS Next 3Y70.66%
5. Dividend
5.1 Amount
FENC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FENNEC PHARMACEUTICALS INC
NASDAQ:FENC (5/31/2024, 7:00:00 PM)
After market: 6.78 0 (0%)6.78
-0.07 (-1.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap183.74M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 226 | ||
| Fwd PE | 11.98 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.19
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 94.39% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 13.87% | ||
| PM (TTM) | 6.33% | ||
| GM | 96.16% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 9.95 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.93 | ||
| Quick Ratio | 6.72 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)103.03%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y190.57%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1296.34%
Revenue growth 3Y400.02%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y